ArticleJournal of applied toxicology : JAT2026
Silica Promotes Silicosis via the ROS/NF-κB p65 Signaling-Activated Hypoxia-Lactate Axis in Rats.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hypoxia occurs during silicosis progression; however, the mechanisms by which silica induces hypoxia and its precise role in the pathogenesis remain poorly understood. In this study, 50 male rats were assigned to five groups: a control group, a model group, and three intervention groups. The rats in the model and intervention groups were intratracheally administered a silica suspension only once, whereas the control rats were intratracheally administered phosphate buffer solution (PBS). Then the rats in intervention groups received daily intravenous injections of N-acetylcysteine (NAC) (at doses of 20, 40, and 80 mg/kg, respectively) while the rats in control and model groups received PBS injections. After 60 days, the lung samples were harvested for histopathologic evaluation, and the hypoxia-related proteins (nuclear factor-κB p65 [NF-κB p65], hypoxia-inducible factor-1α [HIF-1α], and vascular endothelial growth factor A [VEGFA]), lactate-metabolism markers (glucose transporter type 1 [GLUT1] and lactate dehydrogenase A [LDHA]), and pulmonary-injury indicators (interleukin-1β [IL-1β] and transforming growth factor-β1 [TGF-β1]) were quantified using Western blot. The results showed that compared with the control group, the lung of the model group exhibited obvious damage and collagen deposition, accompanied by upregulation of the aforementioned cytokines. When NAC was employed to inhibit silica-induced ROS, all of the above phenomena were reversed in a dose-dependent manner. These findings indicated that silica induced pulmonary hypoxia via the ROS/NF-κB p65 pathway, which subsequently triggered inflammation and fibrosis through lactic acid fermentation, ultimately leading to silicosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.